News & Updates
Filter by Specialty:
Show Multimedia Only

Bemarituzumab extends survival in FGFR2b-overexpressing gastric cancer
07 Nov 2025
byStephen Padilla
The use of bemarituzumab in combination with chemotherapy provides statistically significant survival benefits among patients with advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction cancer (G/GEJC) in the primary analysis of the phase III FORTITUDE-101 trial.








